Conference Track

Management of Treatment-Experienced Patients

Source: CCO Independent Conference Coverage of the 2008 Conference on Retroviruses and Opportunistic Infections*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

No Virologic Benefit of Dose Escalation of PIs in Patients With Normalized Inhibitory Quotient ≤ 1
Improved Outcomes in SMART Study Patients Resuming ART but With Residual Effects of Treatment Interruption
VICTOR-E1: Week 48 Virologic and Immunologic Responses to Vicriviroc Plus OBR in Antiretroviral-Experienced Patients
Lower Incidence of Failure on Second HAART Regimen, but Mortality Risk Remains High
DELPHI: Darunavir/Ritonavir Safe, Well Tolerated, Effective in Treatment-Experienced Children and Adolescents
BENCHMRK-1: Raltegravir Plus OBR Provides Durable Virologic Efficacy Through 48 Weeks in Multiclass-Resistant Patients
BENCHMRK-2: Efficacy of Raltegravir Plus OBR in Multiclass-Resistant Patients Sustained Through Week 48
DUET-1: Etravirine Plus Darunavir/Ritonavir-Containing OBR Superior to OBR Alone at Week 48 in Treatment-Experienced Patients With Baseline NNRTI Resistance
DUET-2: Etravirine Plus Darunavir/Ritonavir-Containing OBR Superior to OBR Alone at Week 48 in Treatment-Experienced Patients With Baseline NNRTI Resistance
48-Week Pooled Data From MOTIVATE 1 and 2 Confirm Durable Efficacy, Safety of Maraviroc in Treatment-Experienced Patients With R5 HIV-1
Apricitabine Safe, Well Tolerated Through 24 Weeks in Treatment-Experienced Patients With M184V
Novel NRTI Amdoxovir Demonstrates Potent Synergistic Activity With Zidovudine, With No Notable Adverse Effects
Increased Risk for Disease Progression With Longer Delay Until Regimen Modification in Patients Failing First-Line NNRTI-Based Treatment

Expert Analysis

Management of Treatment-Experienced Patients

Faculty:

Joseph J. Eron, Jr., MD
W. David Hardy, MD
Kimberly Y. Smith, MD, MPH

Learning Objectives

Upon completion of this activity, participants should be able to:

Recount the results of the BENCHMRK, DUET, and MOTIVATE trials of newly approved agents for treatment-experienced patients
Discuss the new analysis of data from the SMART study of antiretroviral treatment interruption in HIV-infected patients
Describe the results of a trial of therapeutic drug monitoring to guide dosages of drugs for patients with drug-resistant virus

CREDIT INFORMATION

Release Date: 03/24/08

Expiration Date: 03/23/09

Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Registered Nurses: 1.5 Nursing contact hours

Pharmacists: 1.5 contact hours (0.15 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.